Raymond James Financial Inc. Purchases Shares of 537,530 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Raymond James Financial Inc. purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, Holdings Channel reports. The fund purchased 537,530 shares of the company’s stock, valued at approximately $2,500,000.

Several other hedge funds have also recently bought and sold shares of the company. EP Wealth Advisors LLC purchased a new stake in GoodRx during the 3rd quarter worth approximately $73,000. Versor Investments LP purchased a new stake in shares of GoodRx during the fourth quarter worth approximately $54,000. Verus Capital Partners LLC purchased a new position in GoodRx in the fourth quarter worth approximately $55,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of GoodRx during the 4th quarter worth $56,000. Finally, Sanctuary Advisors LLC purchased a new position in GoodRx in the third quarter valued at $85,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Down 0.4 %

GDRX opened at $4.50 on Friday. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The business has a 50-day moving average of $4.77 and a two-hundred day moving average of $5.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -150.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GDRX. KeyCorp lowered their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Morgan Stanley decreased their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Wells Fargo & Company reduced their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Citigroup dropped their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, GoodRx presently has an average rating of “Moderate Buy” and a consensus target price of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.